ArticleScientific reports2024
Development and validation of a nomogram for failure to collect oocytes in POSEIDON Groups 3 and 4 undergoing IVF/ICSI treatment.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to develop and validate a predictive model for failure to collect oocytes in the Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) Groups 3 and 4 during their first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycle. A retrospective analysis was conducted on patients in POSEIDON Groups 3 and 4 who underwent their first IVF/ICSI cycle at our center from January 2016 to December 2023. A total of 2,373 patients were randomly assigned to the training or validation cohort at a ratio of 6:4. Univariate analysis, the least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analysis were used to identify the risk factors. It revealed that the anti-Müllerian hormone (AMH) concentration, controlled ovarian stimulation (COS) protocols, the number of follicles ≥ 14 mm on the day of trigger, and the change in estradiol level between the day before trigger and the trigger day (ΔE2) were the independent predictors. A nomogram was constructed accordingly. The areas under the receiver operating characteristic curves (ROC) of the training and the validation cohorts were 0.868 (95% CI: 0.835-0.902) and 0.860 (95% CI: 0.823-0.897), respectively. The calibration curve showed that the predicted risk of the model was in good agreement with the actual results. Decision curve analysis (DCA) demonstrated the clinical value of this nomogram. Our nomogram provides a practical and user-friendly tool for clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.